Moderna in 2026: What the Wins and Losses Are Telling Us
Our latest podcast on the pattern across Moderna's pipeline, and why INT is the test that matters.
Welcome back to Biotech Blueprint!
You can listen to this episode on YouTube, Spotify or Apple Podcasts.
In the latest joint podcast episode by Biotech Blueprint × Biotech Capital Compass, we zoom in on Moderna and where the company stands in 2026. We work through the Q1 earnings beat, the unprecedented FDA refusal-to-file on mRNA-1010, the CMV Phase 3 failure, the Vertex cystic fibrosis wind down, and the individualized neoantigen therapy (INT) program that has moved to the center of the pipeline. The short companion piece below picks up one thread from the conversation, which is the pattern across Moderna’s wins and losses, and what it suggests about where the platform actually works.
Here’s a link to our previous mRNA podcast episodes:
The successes are all acute. COVID-19, RSV via mRESVIA, the seasonal flu candidate, INT. Each one needs a burst of antigen or a pulse of immune training, and then the body takes it from there. The disappointments are the opposite. CMV is a latent virus that hides intracellularly for life and needs durable, often mucosal immunity to keep suppressed. The Vertex-partnered inhaled mRNA program for CF patients without CFTR protein required continuous replacement of a protein the body cannot make on its own. Both programs were asking the platform to do something it isn’t really built to do.
The biology is straightforward. An mRNA-LNP delivers its cargo into a cell, the ribosomes translate it for a day or two, cytosolic nucleases degrade the mRNA, the LNP clears, and detectable protein is gone within a week or two. Modified nucleosides like N1-methylpseudouridine stretch the translation window a bit and dampen innate sensing, but they do not change the fundamental kinetics. mRNA is, by design, a short-burst technology. That is exactly what you want for a vaccine. It is much harder to make it the right tool for sustained protein replacement, or for the kind of tissue-resident memory T cell response you would want against a virus that is going to live in your body forever.
Hartaj framed the underlying question on the episode this way:
“…One of the things that Moderna is having to go through right now is figure out where is it really that the mRNA modality can work.”
— Hartaj Singh (Biotech Capital Compass)
One way to read the last year of Moderna news is that the platform has been answering that question for them. The successes mark out the shape of what it does well and the failures mark out where it doesn’t. The strategic pivot toward oncology and acute respiratory, and away from latent viruses and chronic protein replacement, looks less like a retreat under cash pressure and more like the company drawing the right roadmap.
That makes INT (mRNA-4157) the cleanest test of where this goes. Each product codes for up to 34 patient-specific neoantigens, selected from tumor sequencing by predicting which mutated peptides will bind that patient’s HLA molecules and present on the tumor surface where cytotoxic T cells can find them. Melanoma is the natural first indication because it carries one of the highest tumor mutational burdens of any solid tumor, which gives the selection pipeline more candidates to choose from. Non-small cell lung cancer extends the test to a much larger patient population. INT plays to what mRNA is good at. A focused immune-training event, then the patient’s T cells do the work. If the melanoma signal holds in NSCLC, the read above is probably right. If it doesn’t, mRNA’s reach is narrower than even this piece is suggesting.
Everything else from the episode is near-term noise. The Q1 earnings beat was helpful but ambiguous, since Q1 is seasonally weak and expectations had been cut. The August 5 PDUFA decision on mRNA-1010 will tell us more about whether the regulatory environment is functionally hostile to mRNA respiratory vaccines under this administration than it will about the trial itself.
One quick teaser for next time. The thread we deliberately did not pull on this week is the role of machine learning in INT. The FDA has indicated it wants the neoantigen selection algorithm submitted as part of the regulatory package, which is the first time we are aware of an AI/ML system being treated as a regulated component of a therapy rather than as a tool sitting upstream of it. That is a bigger story than it sounds, and it gets its own episode.
Three Takeaways
1. Moderna’s successes and failures cluster along one axis. Acute, episodic, pulse-style indications on one side. Sustained, latent, chronic indications on the other.
2. The strategic pivot reads more cleanly as realignment. The company is moving toward indications where the biology fits.
3. INT is the test. The 2026 readouts will tell us whether the platform is broadly useful in oncology, or whether even oncology turns out to be narrower than we hope.
Listen to the full episode on YouTube, Spotify, or Apple Podcasts. Our next episode picks up the thread on AI, machine learning, and what it means when the algorithm itself becomes part of the drug.
Thanks for reading Biotech Blueprint!
DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.
DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.
LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.
Photo credit: Moderna
Really interesting framing. I wonder if part of the challenge is distinguishing today’s mRNA-LNP product-market fit from the platform’s eventual ceiling. Acute applications seem clearly aligned with what the technology does well today, but chronic or repeat-dose settings may depend on whether delivery, tolerability, immune friction and exposure control can be engineered far enough without breaking the commercial logic.